1. Home
  2. VYGR vs TSI Comparison

VYGR vs TSI Comparison

Compare VYGR & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.79

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Logo TCW Strategic Income Fund Inc.

TSI

TCW Strategic Income Fund Inc.

HOLD

Current Price

$4.61

Market Cap

221.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VYGR
TSI
Founded
2013
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
194.0M
221.7M
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
VYGR
TSI
Price
$3.79
$4.61
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$17.00
N/A
AVG Volume (30 Days)
527.4K
247.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
7.46%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,135,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$71.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.65
$4.58
52 Week High
$5.55
$5.06

Technical Indicators

Market Signals
Indicator
VYGR
TSI
Relative Strength Index (RSI) 47.48 21.98
Support Level $2.79 $4.58
Resistance Level $3.73 $4.95
Average True Range (ATR) 0.21 0.06
MACD 0.00 -0.02
Stochastic Oscillator 54.65 10.00

Price Performance

Historical Comparison
VYGR
TSI

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.

Share on Social Networks: